Ledger. Australian venture funding, tracked

Company

BLUE KNIGHT

a joint initiative between Johnson & Johnson Innovation and BARDA designed to accelerate novel potential solutions for future pandemics

Coverage

Stories naming BLUE KNIGHT. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

2 deals

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

Melbourne pharmaceutical company ENA Respiratory has received US$5 million from California's Flu Lab to advance clinical testing of its nasal immune-boosting antiviral candidate INNA-051.

Also Brandon Capital portfolio

Something wrong? Tell us